

# **Global Regenerative Medicines Market: Focus on Products, Applications, 17 Countries' Data and Competitive Landscape - Analysis and Forecast, 2020-2030**

<https://marketpublishers.com/r/G44AE2F752F5EN.html>

Date: April 2021

Pages: 264

Price: US\$ 5,000.00 (Single User License)

ID: G44AE2F752F5EN

## **Abstracts**

Market Report Coverage - Regenerative Medicines

Market Segmentation

Product – Tissue Engineering (Allogeneic Tissue, Autologous Tissue, Xenogeneic Tissue, and Synthetic Tissue), Stem Cells (Stem Cell Services and Stem Cell Therapies), and Cell and Gene Therapy (Car-T Cell Therapy, Gene Therapy, Other Cell Therapies)

Application – Orthopedic and Musculoskeletal, Oncology, Wound Care, Cardiology, Immunology, Dermatology, and Other Applications

Regional Segmentation

North America – U.S., and Canada

Europe – Germany, U.K., France, Italy, Spain, Netherlands, Russia, and Rest-of-Europe

Asia-Pacific – China, Japan, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific

Latin America – Brazil, Mexico, and Rest-of-Latin America

Rest-of-the-World

### Growth Drivers

Increasing Consolidation Among Healthcare Juggernauts

Rising Number of Clinical Trials for Regenerative Therapies

A Favorable Regulatory Environment to Accelerate Approvals and Market Entry

A Rising Awareness for Stem Cell Therapeutics

### Market Challenges

Lack of Reliable Vector Production for Cell and Gene Therapy

Exorbitant Cost of Next-Generation Therapies

### Market Opportunities

Drug Approvals and Strong Pipeline of Cell and Gene Therapies

Multiple Investments in Expansion of cGMP Units

Innovations in Regenerative Medicine

### Key Companies Profiled

AbbVie, Inc., Baxter International Inc., Becton, Dickinson and Company, Dendreon Pharmaceuticals LLC, F. Hoffmann-La Roche Ltd., FUJIFILM Holdings Corporation, Gilead Sciences, Inc., Integra LifeSciences Holdings Corporation, Johnson & Johnson, Medtronic plc, Mesoblast Ltd., Novartis International A.G., NuVasive, Inc., Organogenesis Holdings, Inc., Smith & Nephew plc, Stryker Corporation, Vericel

Corporation, and Zimmer Biomet Holdings, Inc.

Key Questions Answered in this Report:

What are the major market drivers, challenges, and opportunities and their respective impacts on the global regenerative medicines market?

What is the potential impact of advancement in therapeutics among emerging segments of the global regenerative medicines market?

What is the current market demand along with future demand for the global regenerative medicines market?

What are the key regulatory hurdles for industry players looking to enter this highly dynamic market?

What are the key development strategies that are implemented by the major players in order to sustain the competitive market?

How is each of the segments of the market expected to grow during the forecast period from 2020 to 2030 based on each segment? Following are the segments:

Product

Application

Regions, namely, North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World (RoW)

Who are the leading players with significant offerings to the global regenerative medicines market? What is the expected market share for each of these leading players?

Which emerging companies are anticipated to be highly disruptive in the future, and what are their key strategies for sustainable growth in the global regenerative medicines market?

How is the underlying cell and gene therapy segment pushing the boundaries of regenerative medicine across the world? What are the next-generation therapies

within this segment?

## Market Overview

BIS healthcare experts have found cell and gene therapy to be one of the most rapidly evolving and dynamic markets, and the global market for regenerative medicines is predicted to grow at a CAGR of 13.99% over the forecast period of 2020-2030. The market is driven by certain factors, including increasing consolidation among healthcare juggernauts, rising number of clinical trials for regenerative therapies, a favorable regulatory environment to accelerate approvals and market entry, and rising awareness for stem cell therapeutics, that are fueling the growth of the global regenerative medicines market.

Regenerative medicine is challenging the current healthcare practices by targeting the treatment of the root causes of disease and disorders, transforming it into an incredibly exciting space. However, these advancements have not come without significant challenges and uncertainties, which will also further need to be overcome to realize the full potential of regenerative medicine.

Cell and gene therapies, under the regenerative umbrella, are slowly and steadily becoming a healthcare standard, particularly in developed regions such as the U.S. and Europe, where already established markets for tissue engineering and stem cell have largely been responsible for driving the global regenerative medicine phenomenon. Cell and gene therapies, though advancing at a rapid pace, have primarily been targeted for hematological malignancies. However, the same potential has not been replicated in solid tumor applications, consequently creating demand for cell therapies focusing on solid tumors. As a result, the industry is now moving toward the research and subsequent clinical translation of next-generation therapies, led by natural killer (NK) cells, which offer a viable option for solid tumors as well. Such trends are consistently propelling the industry toward realizing the true potential of precision medicine.

Within the research report, the market is segmented on the basis of products, applications, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

## Competitive Landscape

The global regenerative medicines market is currently witnessing several developments, primarily aimed toward bringing new products to support clinicians for the treatment of life-threatening disorders. Major manufacturers of regenerative medicine products are actively involved in undertaking significant business strategies in order to translate success in research and development into the commercial clinical setting. Although tissue engineering and stem cells remain the dominating product segments, the advent of cell and gene therapy has revolutionized the regenerative medicine phenomenon, moving it more toward the precision medicine space.

On the basis of region, North America holds the largest share of the regenerative medicines market due to a high number of active advanced therapeutic medicinal product trials, massive government funding, expansion activities by major companies, and an overall high adoption rate for advancing therapies. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period, 2020-2030.

## Contents

### EXECUTIVE SUMMARY

### 1 PRODUCT DEFINITION AND MARKET SCOPE

- 1.1 Inclusion and Exclusion
- 1.2 Scope of Work
- 1.3 Key Questions Answered in the Report

### 2 RESEARCH METHODOLOGY

- 2.1 Primary Data Sources
- 2.2 Secondary Data Sources
- 2.3 Market Estimation Model
- 2.4 Criteria for Company Profiling

### 3 MARKET OVERVIEW

- 3.1 Clinical Importance of Regenerative Medicine
- 3.2 Market Footprint
- 3.3 Impact of COVID-19

### 4 MARKET DYNAMICS

- 4.1 Impact Analysis
- 4.2 Market Drivers
  - 4.2.1 Increasing Consolidation in the Regenerative Medicines Market
  - 4.2.2 Rising Number of Clinical Trials
  - 4.2.3 Favorable Regulatory Environment
  - 4.2.4 Rising Awareness for Stem Cell Therapeutics
- 4.3 Market Restraints
  - 4.3.1 Lack of Reliable Vector Production for Cell and Gene Therapy
  - 4.3.2 Exorbitant Cost of Next-Generation Therapies
- 4.4 Opportunities
  - 4.4.1 Drug Approvals and Strong Pipeline of Cell and Gene Therapies
  - 4.4.2 Multiple Investments in Expansion of cGMP Units
  - 4.4.3 Innovations in Regenerative Medicine

## **5 INDUSTRY INSIGHTS**

- 5.1 Overview
- 5.2 Legal and Regulatory Framework in the U.S.
  - 5.2.1 Cell and Gene Therapy
    - 5.2.1.1 Cell and Gene Therapy Manufacturing QC
      - 5.2.1.1.1 Product Testing
        - 5.2.1.1.1.1 Microbial Testing
        - 5.2.1.1.1.2 Identity
        - 5.2.1.1.1.3 Purity
        - 5.2.1.1.1.4 Potency
        - 5.2.1.1.1.5 Viability
        - 5.2.1.1.1.6 Cell Number/Dose
      - 5.2.1.1.2 Stem Cell Therapy
      - 5.2.1.1.3 Tissue-Engineered Products
- 5.3 Legal and Regulatory Framework in Europe
- 5.4 Legal and Regulatory Framework in Asia-Pacific
  - 5.4.1 China
  - 5.4.2 Japan

## **6 GLOBAL REGENERATIVE MEDICINES MARKET: COMPETITIVE INSIGHTS**

- 6.1 Overview
- 6.2 Synergistic Activities
- 6.3 Product Approval
- 6.4 Mergers and Acquisitions
- 6.5 Business Expansion and Funding
- 6.6 Product Launches and Upgradations
- 6.7 Market Share Analysis, 2019-2020
  - 6.7.1 Market Share Analysis for Global Regenerative Medicines Market (Tissue Engineering), 2019-2020
  - 6.7.2 Market Share Analysis for Global Regenerative Medicines Market (Cell and Gene Therapy), 2019-2020
  - 6.7.3 Market Share Analysis for Global Regenerative Medicines Market (Stem Cell Therapy), 2019-2020
- 6.8 Growth Share Analysis
  - 6.8.1 Growth Share Analysis (by Company)
  - 6.8.2 Growth Share Analysis (by Product)
  - 6.8.3 Growth Share Analysis (by Application)

## **7 GLOBAL REGENERATIVE MEDICINES MARKET (BY PRODUCT TYPE), \$MILLION, 2019-2030**

- 7.1 Overview
- 7.2 Tissue Engineering
  - 7.2.1 Allogeneic Tissue
  - 7.2.2 Autologous Tissue
  - 7.2.3 Xenogeneic Tissue
  - 7.2.4 Synthetic Tissue
  - 7.2.5 Other Tissues
- 7.3 Stem Cells
  - 7.3.1 Stem Cell Services
  - 7.3.2 Stem Cell Therapy
- 7.4 Cell and Gene Therapy
  - 7.4.1 Cell Therapy
    - 7.4.1.1 Cell Therapy (by Type)
  - 7.4.2 Gene Therapy

## **8 GLOBAL REGENERATIVE MEDICINES MARKET (BY APPLICATION), \$MILLION, 2019-2030**

- 8.1 Overview
- 8.2 Orthopedic and Musculoskeletal
- 8.3 Oncology
- 8.4 Wound Care
- 8.5 Cardiology
- 8.6 Immunology
- 8.7 Dermatology
- 8.8 Other Applications

## **9 GLOBAL REGENERATIVE MEDICINES MARKET (BY REGION), \$MILLION, 2019-2030**

- 9.1 Overview
- 9.2 North America
  - 9.2.1 U.S.
  - 9.2.2 Canada
- 9.3 Europe



- 9.3.1 Germany
- 9.3.2 France
- 9.3.3 Italy
- 9.3.4 U.K.
- 9.3.5 Spain
- 9.3.6 Russia
- 9.3.7 Netherlands
- 9.3.8 Rest-of-Europe
- 9.4 Asia-Pacific
  - 9.4.1 China
  - 9.4.2 Japan
  - 9.4.3 South Korea
  - 9.4.4 Australia
  - 9.4.5 India
  - 9.4.6 Singapore
  - 9.4.7 Rest-of-Asia-Pacific
- 9.5 Latin America
  - 9.5.1 Brazil
  - 9.5.2 Mexico
  - 9.5.3 Rest-of-Latin America
- 9.6 Rest-of-the-World (RoW)

## **10 COMPANY PROFILES**

- 10.1 Overview
- 10.2 AbbVie, Inc.
  - 10.2.1 Company Overview
  - 10.2.2 Role of AbbVie, Inc. in Global Regenerative Medicines Market
  - 10.2.3 Financials
  - 10.2.4 Key Insights About Financial Health of the Company
  - 10.2.5 SWOT Analysis
- 10.3 Baxter International Inc.
  - 10.3.1 Company Overview
  - 10.3.2 Role of Baxter International Inc. in Global Regenerative Medicines Market
  - 10.3.3 Financials
  - 10.3.4 Key Insights About Financial Health of the Company
  - 10.3.5 SWOT Analysis
- 10.4 Becton, Dickinson and Company
  - 10.4.1 Company Overview

#### 10.4.2 Role of Becton, Dickinson and Company in the Global Regenerative Medicines Market

##### 10.4.3 Financials

##### 10.4.4 Key Insights About Financial Health of the Company

##### 10.4.5 SWOT Analysis

#### 10.5 Dendreon Pharmaceuticals LLC.

##### 10.5.1 Company Overview

#### 10.5.2 Role of Dendreon Pharmaceuticals LLC. in the Global Regenerative Medicines Market

##### 10.5.3 SWOT Analysis

#### 10.6 F. Hoffmann-La Roche Ltd

##### 10.6.1 Company Overview

#### 10.6.2 Role of F. Hoffmann-La Roche Ltd. in the Global Regenerative Medicines Market

##### 10.6.3 Financials

##### 10.6.4 Key Insights About Financial Health of the Company

##### 10.6.5 SWOT Analysis

#### 10.7 FUJIFILM Holdings Corporation

##### 10.7.1 Company Overview

#### 10.7.2 Role of FUJIFILM Holdings Corporation in the Global Regenerative Medicines Market

##### 10.7.3 Financials

##### 10.7.4 Key Insights About Financial Health of the Company

##### 10.7.5 SWOT Analysis

#### 10.8 Gilead Sciences, Inc.

##### 10.8.1 Company Overview

#### 10.8.2 Role of Gilead Sciences, Inc. in the Global Regenerative Medicines Market

##### 10.8.3 Financials

##### 10.8.4 Key Insights About Financial Health of the Company

##### 10.8.5 SWOT Analysis

#### 10.9 Integra LifeSciences Holdings Corporation

##### 10.9.1 Company Overview

#### 10.9.2 Role of Integra LifeSciences Holdings Corporation in Global Regenerative Medicines Market

##### 10.9.3 Financials

##### 10.9.4 Key Insights About Financial Health of the Company

##### 10.9.5 SWOT Analysis

#### 10.1 Johnson & Johnson

##### 10.10.1 Company Overview

- 10.10.2 Role of Johnson & Johnson in the Global Regenerative Medicines Market
- 10.10.3 Financials
- 10.10.4 Key Insights About Financial Health of the Company
- 10.10.5 SWOT Analysis
- 10.11 Medtronic plc
  - 10.11.1 Company Overview
  - 10.11.2 Role of Medtronic plc in the Global Regenerative Medicines Market
  - 10.11.3 Financials
  - 10.11.4 Key Insights About Financial Health of the Company
  - 10.11.5 SWOT Analysis
- 10.12 Mesoblast Ltd
  - 10.12.1 Company Overview
  - 10.12.2 Role of Mesoblast Ltd in the Global Regenerative Medicines Market
  - 10.12.3 Financials
  - 10.12.4 Key Insights About Financial Health of the Company
  - 10.12.5 SWOT Analysis
- 10.13 Novartis International AG
  - 10.13.1 Company Overview
  - 10.13.2 Role of Novartis International AG in the Global Regenerative Medicines Market
  - 10.13.3 Financials
  - 10.13.4 Key Insights About Financial Health of the Company
  - 10.13.5 SWOT Analysis
- 10.14 NuVasive, Inc.
  - 10.14.1 Company Overview
  - 10.14.2 Role of NuVasive, Inc. in the Global Regenerative Medicines Market
  - 10.14.3 Financials
  - 10.14.4 Key Insights About Financial Health of the Company
  - 10.14.5 SWOT Analysis
- 10.15 Organogenesis Holdings Inc.
  - 10.15.1 Company Overview
  - 10.15.2 Role of Organogenesis Holdings, Inc. in the Global Regenerative Medicines Market
  - 10.15.3 Financials
  - 10.15.4 Key Insights About the Financial Health of the Company
  - 10.15.5 SWOT Analysis
- 10.16 Smith & Nephew plc
  - 10.16.1 Company Overview
  - 10.16.2 Role of Smith & Nephew plc in the Global Regenerative Medicines Market

- 10.16.3 Financials
- 10.16.4 Key Insights About Financial Health of the Company
- 10.16.5 SWOT Analysis
- 10.17 Stryker Corporation
  - 10.17.1 Company Overview
  - 10.17.2 Role of Stryker Corporation in the Global Regenerative Medicines Market
  - 10.17.3 Financials
  - 10.17.4 Key Insights About Financial Health of the Company
  - 10.17.5 SWOT Analysis
- 10.18 Vericel Corporation
  - 10.18.1 Company Overview
  - 10.18.2 Role of Vericel Corporation in the Global Regenerative Medicines Market
  - 10.18.3 Financials
  - 10.18.4 Key Insights About Financial Health of the Company
  - 10.18.5 SWOT Analysis
- 10.19 Zimmer Biomet Holdings, Inc.
  - 10.19.1 Company Overview
  - 10.19.2 Role of Zimmer Biomet Holdings, Inc. in the Global Regenerative Medicines Market
  - 10.19.3 Financials
  - 10.19.4 Key Insights About Financial Health of the Company
  - 10.19.5 SWOT Analysis

## List Of Tables

### LIST OF TABLES

Table 3.1: Key Products of Cell and Gene Therapy Market

Table 4.1: Impact Analysis

Table 4.2: Key Cell and Gene Therapies with FDA Expedited Review

Table 4.3: Range of Cost for Regenerative Therapies

Table 7.1: List of Key Products

Table 7.2: List of Key Products

Table 7.3: List of Key Products

Table 7.4: List of Key Products

Table 7.5: List of Key Products

Table 7.6: List of Key Services

Table 7.7: List of Key Products

Table 7.8: List of Key Products

Table 7.9: List of Key Products

## List Of Figures

### LIST OF FIGURES

Figure 1: Global Clinical Landscape for Regenerative Medicine, 2019

Figure 2: Impact Analysis on the Global Regenerative Medicines Market

Figure 3: Global Regenerative Medicines Market (by Product), \$Million, 2019 and 2030

Figure 4: Global Regenerative Medicines Market (by Application), \$Million, 2019 and 2030

Figure 5: Global Regenerative Medicines Market (by Region), Market Snapshot

Figure 6: Global Regenerative Medicines Market (by Companies Profiled), Market Snapshot

Figure 1.1: Global Regenerative Medicines Market Segmentation

Primary Research Methodology

Figure 2.1: Bottom-Up Approach (Segment-Wise Analysis)

Figure 2.2: Top-Down Approach (Segment-Wise Analysis)

Figure 3.1: Global Regenerative Medicines Market, \$Million, 2019-2030

Figure 3.2: Impact of COVID-19 on Global Regenerative Medicines Market

Figure 4.1: Number of Clinical Trials for ATMP (by Phase), 2019

Figure 6.1: Share of Key Developments and Strategies, January 2017-February 2021

Figure 6.2: Share of Synergistic Activities, January 2017-February 2021

Figure 6.3: Share of Product Approvals (by Company), January 2017-February 2020

Figure 6.4: Share of Mergers and Acquisitions (by Company), January 2017-February 2021

Figure 6.4: Business Expansion Activities Share, January 2011-February 2021

Figure 6.5: Share of Product Launches and Upgradations, January 2017-February 2021

Figure 6.6: Market Share Analysis for Global Regenerative Medicines Market (Tissue Engineering), 2019 and 2020

Figure 6.7: Market Share Analysis for Global Regenerative Medicines Market (Cell and Gene Therapy), 2019 and 2020

Figure 6.8: Market Share Analysis for Global Regenerative Medicines Market (Stem Cell Therapy), 2019 and 2020

Figure 6.9: Growth Share Analysis for Global Regenerative Medicines Market (by Company), 2020

Figure 6.10: Growth Share Analysis for Global Regenerative Medicines Market (by Product), 2020-2030

Figure 6.11: Growth Share Analysis for Global Regenerative Medicines Market (by Application), 2020-2030

Figure 7.1: Global Regenerative Medicines Market (by Product Type), \$Million, 2019

and 2030

Figure 7.2: Global Regenerative Medicines Market (by Tissue Engineering), \$Million, 2019-2030

Figure 7.3: Global Regenerative Medicines Market (Allogeneic Tissue), \$Million, 2019-2030

Figure 7.4: Global Regenerative Medicines Market (Autologous Tissue), \$Million, 2019-2030

Figure 7.5: Global Regenerative Medicines Market (Xenogeneic Tissue), \$Million, 2019-2030

Figure 7.6: Global Regenerative Medicines Market (Synthetic Tissue), \$Million, 2019-2030

Figure 7.7: Global Regenerative Medicines Market (Other Tissues), \$Million, 2019-2030

Figure 7.8: Global Regenerative Medicines Market (by Stem Cells), \$Million, 2019-2030

Figure 7.9: Global Regenerative Medicines Market (Stem Cell Services), \$Million, 2019-2030

Figure 7.10: Global Regenerative Medicines Market (Stem Cell Therapy), \$Million, 2019-2030

Figure 7.11: Global Regenerative Medicines Market (by Cell and Gene Therapy), \$Million, 2019-2030

Figure 7.12: Global Regenerative Medicines Market (by Cell Therapy), \$Million, 2019-2030

Figure 7.13: Global Regenerative Medicines Market (by Cell Therapy Type), \$Million, 2019 and 2030

Figure 7.14: Global Regenerative Medicines Market (Gene Therapy), \$Million, 2019-2030

Figure 8.1: Global Regenerative Medicines Market (by Application), \$Million, 2019 and 2030

Figure 8.2: Global Regenerative Medicines Market (Orthopedic and Musculoskeletal), \$Million, 2019-2030

Figure 8.3: Global Regenerative Medicines Market (Oncology), \$Million, 2019-2030

Figure 8.4: Global Regenerative Medicines Market (Wound Care), \$Million, 2019-2030

Figure 8.5: Global Regenerative Medicines Market (Cardiology), \$Million, 2019-2030

Figure 8.6: Global Regenerative Medicines Market (Immunology), \$Million, 2019-2030

Figure 8.7: Global Regenerative Medicines Market (Dermatology), \$Million, 2019-2030

Figure 8.8: Global Regenerative Medicines Market (Other Applications), \$Million, 2019-2030

Figure 9.1: Global Regenerative Medicines Market (by Region), Market Snapshot

Figure 9.2: North America: Market Dynamics

Figure 9.3: North America Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.4: North America Regenerative Medicines Market (by Country), \$Million, 2019 Vs. 2030

Figure 9.5: U.S. Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.6: U.S. Regenerative Medicines Market (by Product), \$Million, 2019-2030

Figure 9.7: Canada Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.8: Canada Regenerative Medicines Market (by Product), \$Million, 2019-2030

Figure 9.9: Europe: Market Dynamics

Figure 9.10: Europe Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.11: Europe Regenerative Medicines Market (by Country), \$Million, 2019 Vs. 2030

Figure 9.12: Germany Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.13: Germany Regenerative Medicines Market (by Product), \$Million, 2019-2030

Figure 9.14: France Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.15: France Regenerative Medicines Market (by Product), \$Million, 2019-2030

Figure 9.16: Italy Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.17: Italy Regenerative Medicines Market (by Product), \$Million, 2019-2030

Figure 9.18: U.K. Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.19: U.K. Regenerative Medicines Market (by Product), \$Million, 2019-2030

Figure 9.20: Spain Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.21: Spain Regenerative Medicines Market (by Product), \$Million, 2019-2030

Figure 9.22: Russia Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.23: Russia Regenerative Medicines Market (by Product), \$Million, 2019-2030

Figure 9.24: Netherlands Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.25: Netherlands Regenerative Medicines Market (by Product), \$Million, 2019-2030

Figure 9.26: Rest-of-Europe Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.27: Rest-of-Europe Regenerative Medicines Market (by Product), \$Million, 2019-2030

Figure 9.28: Asia-Pacific: Market Dynamics

Figure 9.29: Asia-Pacific Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.30: Asia-Pacific Regenerative Medicines Market (by Country), \$Million, 2019 Vs. 2030

Figure 9.31: China Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.32: China Regenerative Medicines Market (by Product), \$Million, 2019-2030

Figure 9.33: Japan Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.34: Japan Regenerative Medicines Market (by Product), \$Million, 2019-2030

Figure 9.35: South Korea Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.36: South Korea Regenerative Medicines Market (by Product), \$Million,



2019-2030

Figure 9.37: Australia Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.38: Australia Regenerative Medicines Market (by Product), \$Million, 2019-2030

Figure 9.39: India Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.40: India Regenerative Medicines Market (by Product), \$Million, 2019-2030

Figure 9.41: Singapore Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.42: Singapore Regenerative Medicines Market (by Product), \$Million, 2019-2030

Figure 9.43: Rest-of-Asia-Pacific Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.44: Rest-of-Asia-Pacific Regenerative Medicines Market (by Product), \$Million, 2019-2030

Figure 9.45: Latin America: Market Dynamics

Figure 9.46: Latin America Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.47: Latin America Regenerative Medicines Market (by Country), \$Million, 2019 Vs. 2030

Figure 9.48: Brazil Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.49: Brazil Regenerative Medicines Market (by Product), \$Million, 2019-2030

Figure 9.50: Mexico Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.51: Mexico Regenerative Medicines Market (by Product), \$Million, 2019-2030

Figure 9.52: Rest-of-Latin America Regenerative Medicines Market, \$Million, 2019-2030

Figure 9.53: Rest-of-Latin America Regenerative Medicines Market (by Product), \$Million, 2019-2030

Figure 9.54: Rest-of-the-World Regenerative Medicines Market, \$Million, 2019-2030

Figure 10.1: Total Number of Companies Profiled

Figure 10.2: AbbVie, Inc.: Overall Product Portfolio

Figure 10.3: AbbVie, Inc.: Overall Financials, 2018-2020

Figure 10.4: AbbVie, Inc.: Revenue (by Segment), 2018-2020

Figure 10.5: AbbVie, Inc.: Revenue (by Region), 2018-2020

Figure 10.6: AbbVie, Inc.: R&D Expenditure, 2018-2020

Figure 10.7: AbbVie, Inc.: SWOT Analysis

Figure 10.8: Baxter International Inc.: Overall Product Portfolio

Figure 10.9: Baxter International Inc.: Overall Financials, 2018-2020

Figure 10.10: Baxter International Inc.: Revenue (by Segment), 2018-2020

Figure 10.11: Baxter International Inc.: Revenue (by Region), 2018-2020

Figure 10.12: Baxter International Inc.: R&D Expenditure, 2018-2020

Figure 10.13: bioMérieux SA: SWOT Analysis

Figure 10.14: Becton, Dickinson and Company: Overall Service Portfolio

Figure 10.15: Becton, Dickinson and Company: Overall Financials, 2018-2020

Figure 10.16: Becton, Dickinson and Company: Revenue (by Segment), 2018-2020

- Figure 10.17: Becton, Dickinson and Company: Revenue (by Region), 2017-2019
- Figure 10.18: Becton, Dickinson and Company: R&D Expenditure, 2018-2020
- Figure 10.19: Becton, Dickinson and Company: SWOT Analysis
- Figure 10.20: Dendreon Pharmaceuticals LLC.: Product Portfolio
- Figure 10.21: Dendreon Pharmaceuticals LLC.: SWOT Analysis
- Figure 10.22: F. Hoffmann-La Roche Ltd.: Overall Product Portfolio
- Figure 10.23: F. Hoffmann-La Roche Ltd.: Pipeline Portfolio
- Figure 10.24: F. Hoffmann-La Roche Ltd.: Overall Financials, 2018-2020
- Figure 10.25: F. Hoffmann-La Roche Ltd.: Revenue (by Segment), 2018-2020
- Figure 10.26: F. Hoffmann-La Roche Ltd.: Revenue (by Region), 2018-2020
- Figure 10.27: F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2018-2020
- Figure 10.28: F. Hoffmann-La Roche Ltd.: SWOT Analysis
- Figure 10.29: FUJIFILM Holdings Corporation: Overall Product Portfolio
- Figure 10.30: FUJIFILM Holdings Corporation: Overall Financials, 2017-2019
- Figure 10.31: FUJIFILM Holdings Corporation: Revenue (by Segment), 2017-2019
- Figure 10.32: FUJIFILM Holdings Corporation: Revenue (by Region), 2017-2019
- Figure 10.33: FUJIFILM Holdings Corporation: R&D Expenditure, 2017-2019
- Figure 10.34: FUJIFILM Holdings Corporation: SWOT Analysis
- Figure 10.35: Gilead Sciences, Inc.: Product Portfolio
- Figure 10.36: Gilead Sciences, Inc.: Pipeline Product Portfolio
- Figure 10.37: Gilead Sciences, Inc.: Overall Financials, 2018-2020
- Figure 10.38: Gilead Sciences, Inc.: Revenue (by Segment), 2018-2020
- Figure 10.39: Gilead Sciences, Inc.: Revenue (by Region), 2018-2020
- Figure 10.40: Gilead Sciences, Inc.: R&D Expenditure, 2018-2020
- Figure 10.41: Gilead Sciences, Inc.: SWOT Analysis
- Figure 10.42: Integra LifeSciences Holdings Corporation: Overall Product Portfolio
- Figure 10.43: Integra LifeSciences Holdings Corporation: Overall Financials, 2018-2020
- Figure 10.44: Integra LifeSciences Holdings Corporation: Revenue (by Segment), 2018-2020
- Figure 10.45: Integra LifeSciences Holdings Corporation: Revenue (by Region), 2018-2020
- Figure 10.46: Integra LifeSciences Holdings Corporation: R&D Expenditure, 2018-2020
- Figure 10.47: Integra LifeSciences Holdings Corporation: SWOT Analysis
- Figure 10.48: Johnson & Johnson: Product Portfolio
- Figure 10.49: Johnson & Johnson: Overall Financials, 2018-2020
- Figure 10.50: Johnson & Johnson: Revenue (by Segment), 2018-2020
- Figure 10.51: Johnson & Johnson: Revenue (by Region), 2018-2020
- Figure 10.52: Johnson & Johnson: R&D Expenditure, 2018-2020
- Figure 10.53: Johnson & Johnson: SWOT Analysis

- Figure 10.54: Medtronic plc: Product Portfolio
- Figure 10.55: Medtronic plc: Overall Financials, 2018-2020
- Figure 10.56: Medtronic plc: Revenue (by Segment), 2018-2020
- Figure 10.57: Medtronic plc: Revenue (by Restorative Therapies Group), 2018-2020
- Figure 10.58: Medtronic plc: Revenue (by Region), 2018-2020
- Figure 10.59: Medtronic plc: R&D Expenditure, 2018-2020
- Figure 10.60: Medtronic plc: SWOT Analysis
- Figure 10.61: Mesoblast Ltd.: Product Portfolio
- Figure 10.62: Mesoblast Ltd.: Product Portfolio
- Figure 10.62: Mesoblast Ltd: Overall Financials, 2018-2020
- Figure 10.63: Mesoblast Ltd: Revenue (by Segment), 2018-2020
- Figure 10.64: Mesoblast Ltd: R&D Expenditure, 2018-2020
- Figure 10.65: Mesoblast Ltd: SWOT Analysis
- Figure 10.66: Novartis International AG: Product Portfolio
- Figure 10.67: Novartis International AG: Pipeline Product Portfolio
- Figure 10.68: Novartis International AG.: Overall Financials, 2018-2020
- Figure 10.69: Novartis International AG: Revenue (by Segment), 2018-2020
- Figure 10.70: Novartis International AG: Revenue (by Region), 2018-2020
- Figure 10.71: Novartis International AG: R&D Expenditure, 2018-2020
- Figure 10.72: Novartis International AG: SWOT Analysis
- Figure 10.73: NuVasive, Inc.: Product Portfolio
- Figure 10.74: NuVasive, Inc.: Overall Financials, 2018-2020
- Figure 10.75: NuVasive, Inc.: Revenue (by Segment), 2018-2020
- Figure 10.76: NuVasive, Inc.: Revenue (by Region), 2018-2020
- Figure 10.77: NuVasive, Inc.: R&D Expenditure, 2018-2020
- Figure 10.78: NuVasive, Inc.: SWOT Analysis
- Figure 10.79: Organogenesis Holdings Inc.: Product Portfolio
- Figure 10.80: Organogenesis Holdings Inc.: Overall Financials, 2017-2019
- Figure 10.81: Organogenesis Holdings Inc.: Revenue (by Segment), 2017-2019
- Figure 10.82: Organogenesis Holdings Inc.: R&D Expenditure, 2017-2019
- Figure 10.83: Organogenesis Holdings Inc.: SWOT Analysis
- Figure 10.84: Smith & Nephew plc: Product Portfolio
- Figure 10.85: Smith & Nephew plc: Overall Financials, 2018-2020
- Figure 10.86: Smith & Nephew plc: Revenue (by Segment), 2018-2020
- Figure 10.87: Smith & Nephew plc: Revenue (by Region), 2018-2020
- Figure 10.88: Smith & Nephew plc: R&D Expenditure, 2018-2020
- Figure 10.89: Smith & Nephew plc: SWOT Analysis
- Figure 10.90: Stryker Corporation: Product Portfolio
- Figure 10.91: Stryker Corporation: Overall Financials, 2018-2020

- Figure 10.92: Stryker Corporation: Revenue (by Segment), 2018-2020
- Figure 10.93: Stryker Corporation: Revenue (by Region), 2018-2020
- Figure 10.94: Stryker Corporation: R&D Expenditure, 2018-2020
- Figure 10.95: Stryker Corporation: SWOT Analysis
- Figure 10.96: Vericel Corporation: Product Portfolio
- Figure 10.97: Vericel Corporation: Overall Financials, 2018-2020
- Figure 10.98: Vericel Corporation: Revenue (by Segment), 2018-2020
- Figure 10.99: Vericel Corporation: R&D Expenditure, 2018-2020
- Figure 10.100: Vericel Corporation: SWOT Analysis
- Figure 10.101: Zimmer Biomet Holdings, Inc.: Product Portfolio
- Figure 10.102: Zimmer Biomet Holdings, Inc.: Overall Financials, 2018-2020
- Figure 10.103: Zimmer Biomet Holdings, Inc.: Revenue (by Segment), 2018-2020
- Figure 10.104: Zimmer Biomet Holdings, Inc.: Revenue (by Region), 2018-2020
- Figure 10.105: Zimmer Biomet Holdings, Inc.: R&D Expenditure, 2018-2020
- Figure 10.106: Zimmer Biomet Holdings, Inc.: SWOT Analysis

## I would like to order

Product name: Global Regenerative Medicines Market: Focus on Products, Applications, 17 Countries' Data and Competitive Landscape - Analysis and Forecast, 2020-2030

Product link: <https://marketpublishers.com/r/G44AE2F752F5EN.html>

Price: US\$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G44AE2F752F5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

